Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Mediwound ( (MDWD) ).
On February 12, 2025, MediWound Ltd. announced the initiation of a pivotal Phase III trial named VALUE to evaluate its product EscharEx for treating venous leg ulcers. This comprehensive trial aims to assess the efficacy and safety of EscharEx, which has shown promise in previous trials, potentially redefining the standard of care for chronic wound debridement. MediWound is conducting this trial across 40 sites in the U.S. and Europe, with strategic collaborations with Solventum, Mölnlycke, and MIMEDX to ensure consistent wound management. This trial, which includes interim analysis in 2026, marks a significant step in MediWound’s strategy to strengthen its market position and commercial potential of EscharEx.
More about Mediwound
MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The company specializes in developing, producing, and commercializing innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries. MediWound’s first drug, NexoBrid, is an FDA- and EMA-approved orphan biologic for eschar removal in severe burns.
YTD Price Performance: -4.11%
Average Trading Volume: 65,457
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $189.2M
For a thorough assessment of MDWD stock, go to TipRanks’ Stock Analysis page.
